Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

HUMAN C1-ESTERASE INHIBITOR vs HUMAN PAPILLOMAVIRUS QUADRIVALENT VACCINE, RECOMBINANT: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

HUMAN C1-ESTERASE INHIBITOR vs HUMAN PAPILLOMAVIRUS QUADRIVALENT VACCINE, RECOMBINANT: Safety Overview

Metric HUMAN C1-ESTERASE INHIBITOR HUMAN PAPILLOMAVIRUS QUADRIVALENT VACCINE, RECOMBINANT
Total FAERS Reports 14,344 120
Deaths Reported 1,403 8
Death Rate 9.8% 6.7%
Hospitalizations 3,966 44
Average Patient Age 42.7 yrs 20.5 yrs
% Female Patients 79.1% 84.5%
Manufacturer Takeda Pharmaceuticals America, Inc. N/A